ANDA Submissions To US FDA Expected To Decline; Generic User Fees For FY 2019 Will Rise
FDA's predictions have been pretty consistent; actual submissions haven't been.
You may also be interested in...
A firm will take ownership of US ANDAs from manufacturers unwilling to pay program fees or withdraw the approved generic drug application; is it a novel concept allowing future marketing options or simply fee avoidance?
Generic industry, FDA discuss potential ways to increase transparency so agency can better estimate when – and even whether – an ANDA receiving a complete response will be returned.
New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.